T cell exclusion, immune privilege, and the tumor microenvironment

Effective immunotherapy promotes the killing of cancer cells by cytotoxic T cells. This requires not only that cancer-specific T cells be generated, but also that these T cells physically contact cancer cells. The coexistence in some patients of cancer cells and T cells that recognize them indicates that tumors may exhibit the phenomenon of immune privilege, in which immunogenic tissue is protected from immune attack. Here, we review the evidence that stromal cells of the tumor microenvironment mediate this restriction by excluding T cells from the vicinity of cancer cells. Overcoming this T cell checkpoint may thus enable optimal immunotherapy.

[1]  S. Rosenberg,et al.  Adoptive cell transfer as personalized immunotherapy for human cancer , 2015, Science.

[2]  P. Sharma,et al.  The future of immune checkpoint therapy , 2015, Science.

[3]  D. Linehan,et al.  CSF1/CSF1R blockade reprograms tumor-infiltrating macrophages and improves response to T-cell checkpoint immunotherapy in pancreatic cancer models. , 2015, Cancer research.

[4]  H. Kohrt,et al.  Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients , 2014, Nature.

[5]  P. Hegde,et al.  MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer , 2014, Nature.

[6]  Sebastian Amigorena,et al.  Dissecting the tumor myeloid compartment reveals rare activating antigen-presenting cells critical for T cell immunity. , 2014, Cancer cell.

[7]  Vivien W. Chan,et al.  Macrophage IL-10 blocks CD8+ T cell-dependent responses to chemotherapy by suppressing IL-12 expression in intratumoral dendritic cells. , 2014, Cancer cell.

[8]  R. Emerson,et al.  PD-1 blockade induces responses by inhibiting adaptive immune resistance , 2014, Nature.

[9]  G. Cline,et al.  Functional polarization of tumour-associated macrophages by tumour-derived lactic acid , 2014, Nature.

[10]  G. Wahl,et al.  Vitamin D Receptor-Mediated Stromal Reprogramming Suppresses Pancreatitis and Enhances Pancreatic Cancer Therapy , 2014, Cell.

[11]  S. Goerdt,et al.  Macrophage activation and polarization: nomenclature and experimental guidelines. , 2014, Immunity.

[12]  L. Coussens,et al.  B cells regulate macrophage phenotype and response to chemotherapy in squamous carcinomas. , 2014, Cancer cell.

[13]  T. Matozaki,et al.  The CD47-SIRPα signalling system: its physiological roles and therapeutic application. , 2014, Journal of biochemistry.

[14]  P. Dessen,et al.  PD-L1 is a novel direct target of HIF-1α, and its blockade under hypoxia enhanced MDSC-mediated T cell activation , 2014, The Journal of experimental medicine.

[15]  G. Coukos,et al.  Tumor Endothelium FasL Establishes a Selective Immune Barrier Promoting Tolerance in Tumors , 2014, Nature Medicine.

[16]  L. Tran,et al.  Pten Null Prostate Epithelium Promotes Localized Myeloid-Derived Suppressor Cell Expansion and Immune Suppression during Tumor Initiation and Progression , 2014, Molecular and Cellular Biology.

[17]  J. C. Love,et al.  In vivo discovery of immunotherapy targets in the tumour microenvironment , 2014, Nature.

[18]  L. Zitvogel,et al.  CCL2/CCR2-dependent recruitment of functional antigen-presenting cells into tumors upon chemotherapy. , 2014, Cancer research.

[19]  R. Weichselbaum,et al.  Targeting the tumor microenvironment with interferon-β bridges innate and adaptive immune responses. , 2014, Cancer cell.

[20]  Eric C. Sorenson,et al.  KIT oncogene inhibition drives intratumoral macrophage M2 polarization , 2013, The Journal of experimental medicine.

[21]  L. Coussens,et al.  CSF1R inhibition delays cervical and mammary tumor growth in murine models by attenuating the turnover of tumor-associated macrophages and enhancing infiltration by CD8+ T cells , 2013, Oncoimmunology.

[22]  T. Okazaki,et al.  A rheostat for immune responses: the unique properties of PD-1 and their advantages for clinical application , 2013, Nature Immunology.

[23]  Derek S. Chan,et al.  Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti–PD-L1 immunotherapy in pancreatic cancer , 2013, Proceedings of the National Academy of Sciences.

[24]  D. Quail,et al.  Microenvironmental regulation of tumor progression and metastasis , 2014 .

[25]  Christina S. Leslie,et al.  CSF-1R inhibition alters macrophage polarization and blocks glioma progression , 2013, Nature Medicine.

[26]  J. Wolchok,et al.  Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti–CTLA-4 therapy against melanoma , 2013, The Journal of experimental medicine.

[27]  Masashi Kato,et al.  Inflammatory monocytes are potent antitumor effectors controlled by regulatory CD4+ T cells , 2013, Proceedings of the National Academy of Sciences.

[28]  Jens-Peter Volkmer,et al.  Engineered SIRPα Variants as Immunotherapeutic Adjuvants to Anticancer Antibodies , 2013, Science.

[29]  J. Wolchok,et al.  Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4 , 2013, The Journal of experimental medicine.

[30]  James O. Jones,et al.  Depletion of stromal cells expressing fibroblast activation protein-α from skeletal muscle and bone marrow results in cachexia and anemia , 2013, The Journal of experimental medicine.

[31]  Huidong Shi,et al.  An inherently bifunctional subset of Foxp3+ T helper cells is controlled by the transcription factor eos. , 2013, Immunity.

[32]  Dai Fukumura,et al.  Vascular normalization as an emerging strategy to enhance cancer immunotherapy. , 2013, Cancer research.

[33]  G. Freeman,et al.  Strength of PD-1 signaling differentially affects T-cell effector functions , 2013, Proceedings of the National Academy of Sciences.

[34]  D. Munn,et al.  Indoleamine 2,3 dioxygenase and metabolic control of immune responses. , 2013, Trends in immunology.

[35]  Sunil Singhal,et al.  Changes in the local tumor microenvironment in recurrent cancers may explain the failure of vaccines after surgery , 2012, Proceedings of the National Academy of Sciences.

[36]  W. Wick,et al.  Tryptophan catabolism in cancer: beyond IDO and tryptophan depletion. , 2012, Cancer research.

[37]  R. Jain,et al.  Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy , 2012, Proceedings of the National Academy of Sciences.

[38]  G. Prendergast,et al.  IDO is a nodal pathogenic driver of lung cancer and metastasis development. , 2012, Cancer discovery.

[39]  C. Drake,et al.  Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. , 2012, The New England journal of medicine.

[40]  David C. Smith,et al.  Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. , 2012, The New England journal of medicine.

[41]  D. Bar-Sagi,et al.  Oncogenic Kras-induced GM-CSF production promotes the development of pancreatic neoplasia. , 2012, Cancer cell.

[42]  N. Jhala,et al.  Tumor-derived granulocyte-macrophage colony-stimulating factor regulates myeloid inflammation and T cell immunity in pancreatic cancer. , 2012, Cancer cell.

[43]  L. Ellis,et al.  Antiangiogenic therapy—evolving view based on clinical trial results , 2012, Nature Reviews Clinical Oncology.

[44]  C. Payne,et al.  Tumor-targeted TNFα stabilizes tumor vessels and enhances active immunotherapy , 2012, Proceedings of the National Academy of Sciences.

[45]  A. Rudensky,et al.  Regulatory T cells: mechanisms of differentiation and function. , 2012, Annual review of immunology.

[46]  Douglas Hanahan,et al.  Accessories to the Crime: Functions of Cells Recruited to the Tumor Microenvironment Prospects and Obstacles for Therapeutic Targeting of Function-enabling Stromal Cell Types , 2022 .

[47]  A. Corti,et al.  Targeting TNF-α to Neoangiogenic Vessels Enhances Lymphocyte Infiltration in Tumors and Increases the Therapeutic Potential of Immunotherapy , 2012, The Journal of Immunology.

[48]  Pierre Validire,et al.  Matrix architecture defines the preferential localization and migration of T cells into the stroma of human lung tumors. , 2012, The Journal of clinical investigation.

[49]  J. Wolchok,et al.  Monocytic CCR2(+) myeloid-derived suppressor cells promote immune escape by limiting activated CD8 T-cell infiltration into the tumor microenvironment. , 2011, Cancer research.

[50]  L. Lazzarato,et al.  Chemokine nitration prevents intratumoral infiltration of antigen-specific T cells , 2011, The Journal of experimental medicine.

[51]  Karin Jirström,et al.  Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy. , 2011, Cancer discovery.

[52]  S. Steinberg,et al.  Durable Complete Responses in Heavily Pretreated Patients with Metastatic Melanoma Using T-Cell Transfer Immunotherapy , 2011, Clinical Cancer Research.

[53]  Drew A. Torigian,et al.  CD40 Agonists Alter Tumor Stroma and Show Efficacy Against Pancreatic Carcinoma in Mice and Humans , 2011, Science.

[54]  R. Schreiber,et al.  Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion , 2011, Science.

[55]  James O. Jones,et al.  Suppression of Antitumor Immunity by Stromal Cells Expressing , 2022 .

[56]  S. Rosenberg,et al.  Phase 2 Trial of Single Agent Ipilimumab (Anti-CTLA-4) for Locally Advanced or Metastatic Pancreatic Adenocarcinoma , 2010, Journal of immunotherapy.

[57]  Douglas B. Evans,et al.  High Levels of Expression of Human Stromal Cell–Derived Factor-1 Are Associated with Worse Prognosis in Patients with Stage II Pancreatic Ductal Adenocarcinoma , 2010, Cancer Epidemiology, Biomarkers & Prevention.

[58]  D. Schadendorf,et al.  Improved survival with ipilimumab in patients with metastatic melanoma. , 2010, The New England journal of medicine.

[59]  V. Engelhard,et al.  Tumor masses support naive T cell infiltration, activation, and differentiation into effectors , 2010, The Journal of experimental medicine.

[60]  S. Rosenberg,et al.  Antiangiogenic agents can increase lymphocyte infiltration into tumor and enhance the effectiveness of adoptive immunotherapy of cancer. , 2010, Cancer research.

[61]  V. Reuter,et al.  Tumor associated endothelial expression of B7-H3 predicts survival in ovarian carcinomas , 2010, Modern Pathology.

[62]  J. Abastado,et al.  Tumor cells disseminate early, but immunosurveillance limits metastatic outgrowth, in a mouse model of melanoma. , 2010, The Journal of clinical investigation.

[63]  Jeffrey W. Pollard,et al.  Macrophage Diversity Enhances Tumor Progression and Metastasis , 2010, Cell.

[64]  S. Hirohashi,et al.  Prognostic significance of CXCL12 expression in patients with colorectal carcinoma. , 2009, American journal of clinical pathology.

[65]  E. Unanue,et al.  Batf3 Deficiency Reveals a Critical Role for CD8α+ Dendritic Cells in Cytotoxic T Cell Immunity , 2008, Science.

[66]  Fabian Kiessling,et al.  Vascular normalization in Rgs5-deficient tumours promotes immune destruction , 2008, Nature.

[67]  P. Gimotty,et al.  Endothelin B receptor mediates the endothelial barrier to T cell homing to tumors and disables immune therapy , 2008, Nature Medicine.

[68]  Z. Trajanoski,et al.  Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome , 2006, Science.

[69]  Gerd Ritter,et al.  Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[70]  S. Steinberg,et al.  Tumor Progression Can Occur despite the Induction of Very High Levels of Self/Tumor Antigen-Specific CD8+ T Cells in Patients with Melanoma , 2005, The Journal of Immunology.

[71]  H. Ohtani,et al.  Intraepithelial CD8+ T-cell-count becomes a prognostic factor after a longer follow-up period in human colorectal carcinoma: possible association with suppression of micrometastasis , 2004, British Journal of Cancer.

[72]  George Coukos,et al.  Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. , 2003, The New England journal of medicine.

[73]  Gordon Stamp,et al.  Multiple actions of the chemokine CXCL12 on epithelial tumor cells in human ovarian cancer. , 2002, Cancer research.

[74]  D. Scadden,et al.  Active movement of T cells away from a chemokine , 2000, Nature Medicine.

[75]  H Nagura,et al.  CD8+ T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer. , 1998, Cancer research.

[76]  D. Carbone,et al.  Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells , 1996, Nature Medicine.

[77]  M. Ladanyi,et al.  Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation. , 1994, The New England journal of medicine.

[78]  S. Riddell,et al.  Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones. , 1992, Science.

[79]  P. Chomez,et al.  A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. , 1991, Science.

[80]  G. Klein,et al.  Demonstration of resistance against methylcholanthrene-induced sarcomas in the primary autochthonous host. , 1960, Cancer research.

[81]  P. Medawar Immunity to homologous grafted skin; the fate of skin homografts transplanted to the brain, to subcutaneous tissue, and to the anterior chamber of the eye. , 1948, British journal of experimental pathology.

[82]  P. Rous,et al.  ON THE CAUSE OF THE LOCALIZATION OF SECONDARY TUMORS AT POINTS OF INJURY , 1914, The Journal of experimental medicine.